Program

MONDAY MAY 21, 2001

7:00-8:00	Breakfast with the Experts (The experts may discuss additional topics to those given below) Peter Neumann ScD, Assistant Professor, Harvard School of Public Health, Boston, Massachusetts, USA Topic: Cost-utility Analyses and Preference Assessment Gerry Oster PhD, Vice President, PAI, Brookline, Massachusetts, USA Topic: Claims Database Analyses and Pragmatic Outcomes Trials A. David Paltiel PhD, Associate Professor of Health Policy and Management, Yale School of Medicine, New Haven, Connecticut, USA Topic: Disease Policy Simulation Models Dennis Revicki PhD, Vice President, MEDTAP International, Bethesda, Maryland, USA Topic: Quality of Life Assessment and FDA Claims
8:00-8:30	Welcome Sean Sullivan PhD ISPOR Annual Meeting Program Chair and Associate Professor, University of Washington, Seattle, Washington, USA Presidential Address Jon C. Clouse RPh, MS ISPOR 2000-2001President and Executive Vice President, Ingenix Pharmaceutical Services, Eden Prairie, Minnesota, USA
8:30-10:00	First Plenary Session — "Federal Policy and Pharmacoeconomics: The New Administration's Assessment" Objective: The objective of this session is to provide an early view of the US Bush Administration's policies on Medicare Rx drug benefit, FDA economic and quality of life claims, patient confidentiality policies, and federal funding for outcomes research. Moderator: Jon C. Clouse RPh, MS Speakers: Louis Rossiter PhD, Deputy Secretary for Operations, Office of the Secretary of Health & Human Resources for the State of Virginia, Richmond, Virginia, USA (invited) Anne Phelps, Special Assistant, Domestic Policy for Health Care, The White House, Washington, DC, USA (invited)
10:00-10:30	Poster Presentations - Session 1 Economic, clinical, quality of life, and preference-based assessment study results on the following diseases will be displayed: Arthritis, Osteoporosis & Muscular-Skeletal Disorders (PAM), Asthma & Respiratory Disorders (PAR), Cancer (PCN), Cardiovascular Disease (PCV), Diabetes (PDB), Eye/Ear/Skin/Dental Diseases (PEE), Gastrointestinal Disorders (PGI)
10:30-12:00	Podium Sessions — 4 Tracks ECONOMIC METHODOLOGY ISSUES - TRACK 1 EM1 RISK ATTITUDE: ASSOCIATION WITH MAGNITUDE OF RISK AND PATIENT CHARACTERISTICS Singer ME, Beaird H, Miller LAN, Case Western Reserve University, Cleveland, OH, USA EM2 THE IMPACT OF HOSPITAL COSTING METHODS ON STATISTICAL POWER IN MULTINATIONAL CLINICAL TRIALS Reed SD1, Friedman JY1, Malenbaum JH1, Gnanasakthy A2, Schulman KA1, 1Duke Clinical Research Institute, Durham, NC, USA; 2Novartis Pharmaceutical Corp, East Hanover, NJ, USA EM3 RESPONSE BIAS AMONG LIKELY CLINICAL TRIAL PARTICIPANTS McDonnell DD, Donohue JA, Consumer Health Sciences, Princeton, NJ, USA EM4 CAN UNIT COSTS BE COMPARED ACROSS WESTERN EUROPEAN COUNTRIES? Brown R1, Hutton J2, Nuijten M3, 1MEDTAP International Inc, Bethesda, MD, USA; 2MEDTAP International Inc, London, UK; 3MEDTAP International, Jisp, Netherlands MEDICAL DEVICE & DIAGNOSTICS - TRACK 2 MD1 COST-EFFECTIVENESS OF AIRLINE DEFIBRILLATORS: IS PEACE OF MIND MORE IMPORTANT THAN SAVING LIVES? Cram P1, Vijan S1, Wolbrink AM2, Fendrick AM1, 1University of Michigan, Ann Arbor, MI, USA; 2Federal Aviation Administration, Oklahoma City, OK, USA MD2 ANALYSIS OF THE IMPACT OF ASSISTIVE LIVING DEVICES ON SELF-ASSESSED HEALTH STATUS RATING Rodney AB, Xiao H, Robertson T, Florida A&M University, Tallahassee, FL, USA MD3 THE DIAGNOSTIC ACCURACY OF 18FDG-PET IN PATIENTS WITH RECURRENT PAPILLARY OR FOLLICULAR THYROID CANCER: A SYSTEMATIC REVIEW Hooft L, Hoekstra OS, University Hospital Vrije Universiteit, Amsterdam, Netherlands MD4 INCLUSION OF INDIRECT COST IN ECONOMIC OUTCOMES ANALYSES OF MEDICAL DEVICES: HOW IMPORTANT IS IT? Subramanian S, Justason BJ, Boston Scientific Corporation, Natick, MA, USA QUALITY OF LIFE & PREFERENCE-BASED MEASURES - TRACK 3 QL1 DOES SOCIOECONOMIC STATUS AFFECT THE VALUATION OF HEALTH? Asada Y1, Stout NK1, Kind P2, 1University of Wisconsin, Madison, WI, USA, 2University of York, York, UK QL2 LOGICAL CONSISTENCY AND THE VALUATION OF HEALTH: AN ANALYSIS OF US SURVEY DATA Craig BM1, Kind P2, 1University of Wisconsin - Madison, Madison, WI, USA; 2University of York, York, UK QL3 QUALITY OF LIFE IN PRODUCT LABELING: A REVIEW OF MARKETED DRUG PRODUCTS Chopra T1, Shah SN12, McLaughlin-Miley C2, Hinton J2, 1University of Michigan, Ann Arbor, MI, USA; 2Pfizer Pharmaceuticals Group, Ann Arbor, MI, USA QL4 QUALITY OF LIFE MESSAGES IN PRESCRIPTION DRUG ADVERTISEMENTS IN LEADING MEDICAL JOURNALS, 1990-99 Zivin K, Neumann P, Harvard School of Public Health, Boston, MA, USA HEALTH POLICY - TRACK 4 HP1 ETHNIC DISPARITY OF COMBINATION RIBAVIRIN/INTERFERON ALFA-2B PRESCRIBING AMONG HEPATITIS C-INFECTED MEMBERS IN A MANAGED CARE ORGANIZATION (MCO) Phillips AL1, Schaffer M2, Mansukani S2, 1Thomas Jefferson University, Philadelphia, PA, USA; 2Health Partners Inc, Philadelphia, PA, USA HP2 THE ROLE OF OUTLIER PAYMENTS IN MEDICARE PATIENTS WITH SEVERE SEPSIS Cooper LM1, Linde-Zwirble WT2, 1Eli Lilly and Company, Indianapolis, IN, USA; 2Health Process Management, Owings Mills, MD, USA HP3 INCORPORATING CLINICAL OUTCOMES AND ECONOMIC CONSEQUENCES INTO DRUG FORMULARY DECISIONS: EVALUATION OF 30 MONTHS OF EXPERIENCE Atherly DE1, Sullivan SD1, Fullerton DS2, Sturm LL2, 1University of Washington, Seattle, WA, USA; 2Regence BlueShield, Seattle, WA, USA HP4 ASSESSING LIFESTYLE DRUGS FOR DRUG BENEFIT FORMULARIES: A COST-UTILITY ANALYSIS OF ORLISTAT AND SIBUTRAMINE FOR THE TREATMENT OF OBESITY IN ADULTS Trakas K1, Oh PI2, Leiter L3, Shear NH2, 1University of Toronto, Toronto, ON, Canada, 2Sunnybrook and Women's College Health Science Centre, Toronto, ON, Canada, 3St. Michael's Hospital, Toronto, ON, Canada
12:00-1:30	Poster Presentations - Session 1, Exhibits and Lunch
1:30-3:00	Issues Panels — 4 Tracks ECONOMIC METHODOLOGY ISSUES - PROPENSITY SCORES - TRACK 1 Chair: Sharon-Lise T. Normand PhD, Associate Professor, Department of Health Care Policy, Harvard Medical School, Boston, MA, USA MEDICAL DEVICE & DIAGNOSTICS - HCFA COVERAGE POLICY FOR NEW MEDICAL TECHNOLOGY - TRACK 2 Chair: Thomas A. Ault MPP, Principle, Health Policy Alternatives, Inc., Washington, DC, USA QUALITY OF LIFE & PREFERENCE-BASED MEASURES - MAPPING FROM HEALTH STATUS TO UTILITIES - TRACK 3 Chair: Leslie Lenert MD, MS, VA San Diego Healthcare System & University of California-San Diego, San Diego, CA, USA HEALTH POLICY - LIFESTYLE DRUGS AND DRUG BENEFIT MANAGEMENT - TRACK 4 Chair: Camille Haltom MS, Healthcare Consultant, Hewitt Associates, Lincolnshire, IL, USA
3:00-3:30	Break
3:30-4:30	Contributed Workshop Presentations — 4 Tracks ECONOMIC METHODOLOGY - TRACK 1 WW1 METHODOLOGICAL COMPLEXITIES IN USING ADMINISTRATIVE CLAIMS DATABASES TO EVALUATE QUALITY OF CARE FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER Hankin CS1, Wright AT2, 1ALZA Corporation, Mountain View, CA, USA; 2Advance PCS, Hunt Valley, MD, USA WW2 USING LINKABLE CLINICAL AND ADMINISTRATIVE CLAIMS DATA TO IMPROVE OUTCOMES RESEARCH: SELECTED CASE STUDIES FROM ONCOLOGY AND DIABETES MELLITUS Menzin J, Lang K, Boston Health Economics, Inc, Waltham, MA, USA WW3 ISSUES AND PROBLEMS ENCOUNTERED IN MODELS ON PREVENTION OF DEEP VENOUS THROMBOSIS (DVT) Annemans L1, Lamotte M1, Huybrechts M2, 1HEDM, Meise, Belgium; 2AstraZeneca, Brussels, Belgium WW4 A NEW APPROACH TO DISEASE MODELING WITH NUMEROUS COMPARATORS AND MULTIPLE DECISION TREES Becker R1, Noe L1, Gore M2, Martino S3, 1Ovation Research Group, Highland Park, IL, USA; 2Avalon Health Solutions, Wilmington, DE, USA; 3John Wayne Cancer Institute, Santa Monica, CA, USA WW5 CREATIVE APPROACHES TO MODELING LIFE EXPECTANCY GAINS FOR ECONOMIC EVALUATION USING PUBLISHED DATA Weinstein MC1, Appadoo S2, 1Harvard School of Public Health, Boston, MA, USA; 2Innovus Research, Inc, Medford, MA, USA WW6 CAN UNIT COSTS BE COMPARED ACROSS WESTERN EUROPEAN COUNTRIES? Hauber AB1, Bala MV2, Fehnel SE3, 1Parametric Research Corporation, Hatboro, PA, USA; 2Centocor, Inc, Malvern, PA, USA; 3RTI Health Solutions, Research Triangle Park, NC, USA MEDICAL DEVICE & DIAGNOSTICS - TRACK 2 WW15 IDENTIFYING THE IMPACT OF A TREATMENT ON OUTCOMES AND COSTS USING OBSERVATIONAL DATA: OVERCOMING SELECTION BIAS Polsky D, Glick HA, University of Pennsylvania, Philadelphia, PA, USA QUALITY OF LIFE & PREFERENCE-BASED MEASURES - TRACK 3 WW17 SELECTING HEALTH-RELATED QUALITY-OF-LIFE MEASURES: FIRST PRINCIPLES Erickson P12, 1Penn State University, State College, PA, USA; 2The On-Line Guide to Quality-of-Life Assessment (OLGA), State College, PA, USA HEALTH POLICY - TRACK 4 WW13 CHALLENGES IN PERFORMING META ANALYSIS IN HEART FAILURE OUTCOMES RESEARCH Mullins CD1, Weiss S1, Fulda T2, 1University of Maryland, Baltimore, MD, USA; 2U.S. Pharmacopeia, Rockville, MD, USA
4:30-5:30	Contributed Workshop Presentations — 4 Tracks ECONOMIC METHODOLOGY - TRACK 1 WW7 BEYOND COST-EFFECTIVENESS: THE STRATEGIC VALUE OF PRODUCTIVITY-RELATED OUTCOMES IN CLINICAL TRIALS, BURDEN OF ILLNESS STUDIES, AND POST-MARKETING RESEARCH Ozminkowski RJ, Goetzel RZ, Crown WC, Long SR, Ling D, The MEDSTAT Group, Inc, Ann Arbor, MI, USA WW8 CONSTRUCTING EPISODES OF CARE FROM CLAIMS DATA: APPLICATIONS TO PHARMACOECONOMIC AND OUTCOMES RESEARCH Huse D1, Portnoy M2, 1PharMetrics, Inc, Watertown, MA, USA; 2Symmetry Health Data Systems, Phoenix, AZ, USA WW9 THE USE OF MULTI-ATTRIBUTE ANALYSIS AND PAIR-WISE COMPARISONS FOR GROUP DECISION-MAKING Hess GP1, Forman E2, 1CareScience, Philadelphia, PA, USA; 2George Washington University, Washington, DC, USA WW10 MULTINATIONAL ECONOMIC STUDIES: LESSONS LEARNED FROM TRIAL-BASED AND MODELLING STUDIES Drummond MF1, Grima D2, 1University of York, Heslington, York, UK; 2Innovus Research Inc, Burlington, ON, Canada WW11 USING MARKOV DECISION MODELS TO DEVELOP OPTIMAL TREATMENT PATHWAYS: AN ILLUSTRATION Bala MV1, Mauskopf JA2, 1Centocor, Inc, Malvern, PA, USA; 2Research Triangle Institute, Research Triangle Park, NC, USA WW12 USE OF MEDICATION COMPLIANCE DATA IN OUTCOME ANALYSES Cramer JA1, Urquhart J23, 1Yale University School of Medicine, West Haven, CT, USA; 2Maastricht University, Maastricht, The Netherlands; 3AARDEX Ltd., Zug, Switzerland HEALTH POLICY - TRACK 4 WW14 MAKING MODELS BETTER Matchar DB1, Samsa GP1, Parmigiani G2, 1Duke University, Durham, NC, USA; 2Johns Hopkins School of Medicine, Baltimore, MD, USA MEDICAL DEVICE & DIAGNOSTICS - TRACK 2 WW16 PATIENT REGISTRIES: THEIR VALUE IN OUTCOMES RESEARCH Russell MW, ICSL Healthcare Research, Waltham, MA, USA QUALITY OF LIFE & PREFERENCE-BASED MEASURES - TRACK 2 WW18 THE ROLE OF HEALTH STATE EXPERIENCE IN LONGITUDINAL CONJOINT ANALYSIS OF PATIENT PREFERENCES Bingham M, Smith G, Triangle Economic Research, Durham, NC, USA
5:30-6:30	Forums STUDENT FORUM THE ISPOR STUDENT NETWORK FORUM Welcome Veronica Sendersky PharmD, Novartis Outcomes Research Fellow, Duke Clinical Research Institute & 2000-2001 ISPOR Student Network Chair, Durham, NC, USA and Zeba Kahn RPh, PhD, Senior Health Outcomes Scientist, GlaxoSmithKline, Research Triangle Park, NC, USA & ISPOR Student Network Advisor ISPOR President's Welcome Jon C. Clouse RPh, MS, ISPOR 2000-2001 President and Executive Vice President, Ingenix Pharmaceutical Services, Eden Prairie, MN, USA ISPOR Chapter Presidents Recognition Invited Presentation: "Everything You Need to Know about Getting That First Job" Cheri Buonaguidi, Vice President, Bench International, Los Angeles, CA, USA MEDICAL DEVICE & DIAGNOSITCS FORUM - TRACK 2 HEALTH TECHNOLOGY ASSESSMENT AND ITS EFFECT ON PATIENT ACCESS Speakers: Jonathan Freudman MD, Medical Advisor, Blue Shield of California, San Francisco, CA, USA (invited) Clifford Goodman PhD, Senior Scientist, Medical Technology, The Lewin Group, Falls Church, VA, USA (invited) QUALITY OF LIFE FORUM - TRACK 3 QUALITY OF LIFE OUTCOMES: CONTROVERSIAL ISSUES & PRACTICAL SOLUTIONS Highlights of four important quality of life outcomes issues will include examples and applications. Presenters from the ISPOR QOL Special Interest Group will contribute practical solutions. Audience discussion will be carried forward to the QOL Special Interest Group Discussion Meeting on Tuesday, May 22nd. Moderator: Nancy Kline Leidy PhD, RN, Medtap International, Bethesda, MD, USA & ISPOR Quality of Life (QoL) Special Interest Group (SIG) Chair Is it QoL, Health Status or Patient Preference? Pennifer Erickson PhD, O.L.G.A., State College, PA, USA & ISPOR QoL SIG Concepts & Definitions Chair How Do We Work Globally? Diane Jacqueline Wilde MSc, Oxford Outcomes, Oxford, UK & ISPOR QoL SIG Translation & Adaptation Chair What Do The Numbers Mean? Joyce Cramer, Yale University School of Medicine, West Haven, CT, USA & ISPOR QoL SIG Interpretation & Meaning Chair How Do We Put a Value on QoL Outcomes? Paul Kind Mphil, University of York, Centre for Health Economics, York, UK & ISPOR QoL SIG Values & Valuation Chair
6:30-8:30	Exhibitor's Open House and Reception
6:30-8:30	QUALITY OF LIFE FORUM SPECIAL INTEREST GROUP - TRANSLATION & ADAPTATION GROUP MEETING - TRACK 3

Contact ISPOR @ info@ispor.org  |  View Legal Disclaimer
©2008 International Society for Pharmacoeconomics and Outcomes Research. All rights reserved under International and Pan-American Copyright Conventions. 
Website design by Eagle Systems USA, Inc.